# The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer

> **NCT07130578** · — · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Bladder Cancer
- Liquid Biopsy

## Interventions

- **DIAGNOSTIC_TEST:** urine tumor DNA/RNA testing

## Key facts

- **NCT ID:** NCT07130578
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07130578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07130578, "The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07130578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*